Literature DB >> 18408020

Gene expression analysis of interferon-beta treatment in multiple sclerosis.

F Sellebjerg1, P Datta, J Larsen, K Rieneck, I Alsing, A Oturai, A Svejgaard, P Soelberg Sørensen, L P Ryder.   

Abstract

Treatment with interferon-beta (IFN-beta) induces the expression of hundreds of genes in blood mononuclear cells, and the expression of several genes has been proposed as a marker of the effect of treatment with IFN-beta. However, to date no molecules have been identified that are stably induced by treatment with IFN-beta. We use DNA microarrays to study gene expression in 10 multiple sclerosis (MS) patients who began de novo treatment with IFN-beta. After the first injection of IFN-beta, the expression of 74 out of 3428 genes changed at least two-fold and statistically significantly (after Bonferroni correction). In contrast, we observed no persisting effects of IFN-beta on gene expression. Among the most strongly induced genes was MXA, which has been used in previous biomarker studies in MS. In addition, the study identified the induction of LGALS9 and TCIR1G, involved in negative regulation of T helper type I immunity and T-cell activation, as novel effects of IFN-beta therapy in MS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408020     DOI: 10.1177/1352458507085976

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  12 in total

Review 1.  The genetics of multiple sclerosis: an up-to-date review.

Authors:  Pierre-Antoine Gourraud; Hanne F Harbo; Stephen L Hauser; Sergio E Baranzini
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

2.  Neutralizing antibodies against interferon-Beta.

Authors:  Per Soelberg Sorensen
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

3.  Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS.

Authors:  S E Bushnell; Z Zhao; C C Stebbins; D Cadavid; A M Buko; E T Whalley; J A Davis; E M Versage; J R Richert; R C Axtell; L Steinman; R Medori
Journal:  Neurology       Date:  2012-05-09       Impact factor: 9.910

4.  Type I IFN signaling in T regulatory cells modulates chemokine production and myeloid derived suppressor cells trafficking during EAE.

Authors:  Shalini Tanwar; Cihan Oguz; Amina Metidji; Eric Dahlstrom; Kent Barbian; Kishore Kanakabandi; Lydia Sykora; Ethan M Shevach
Journal:  J Autoimmun       Date:  2020-07-22       Impact factor: 7.094

Review 5.  The mechanism of action of interferon-β in relapsing multiple sclerosis.

Authors:  Bernd C Kieseier
Journal:  CNS Drugs       Date:  2011-06-01       Impact factor: 5.749

Review 6.  Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Authors:  Per Soelberg Sorensen
Journal:  CNS Drugs       Date:  2022-05-19       Impact factor: 6.497

7.  FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis.

Authors:  F Sellebjerg; M Krakauer; M Khademi; T Olsson; P S Sørensen
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

Review 8.  Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity.

Authors:  Manfred Kunz; Saleh M Ibrahim
Journal:  Mediators Inflamm       Date:  2009-10-26       Impact factor: 4.711

9.  Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis.

Authors:  Daniel Harari; Nadine Kuhn; Renne Abramovich; Keren Sasson; Alla L Zozulya; Paul Smith; Martin Schlapschy; Rina Aharoni; Mario Köster; Raya Eilam; Arne Skerra; Gideon Schreiber
Journal:  J Biol Chem       Date:  2014-09-05       Impact factor: 5.157

10.  Endogenous and recombinant type I interferons and disease activity in multiple sclerosis.

Authors:  Finn Sellebjerg; Martin Krakauer; Signe Limborg; Dan Hesse; Henrik Lund; Annika Langkilde; Helle Bach Søndergaard; Per Soelberg Sørensen
Journal:  PLoS One       Date:  2012-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.